545 CONCORD AVENUE, CAMBRIDGE, MA
Investor Presentation
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
Announces AI-Driven Collaboration to Explore Additional Indications for DA-1241
Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
Shareholder votes
Annual Report to Security Holders
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Q2
Q1
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload